Affiliation:
1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2. Department of Medicine, Weill Cornell University, New York, NY 10065, USA
Abstract
Esophageal adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, is uncommon in the United States, but is associated with a rising incidence in young adults, and has a traditionally poor prognosis. Despite the incremental benefits that have been made with multimodality approaches to locally advanced disease, most patients will go on to develop metastatic disease, and long-term outcomes remain suboptimal. Over the last decade, PET-CT has emerged as a key tool in the management of this disease, with several prospective and retrospective studies evaluating its role in this disease. Herein, we review the key data pertaining to the use of PET-CT in the management of locally advanced esophageal and GEJ adenocarcinoma, with a focus on staging, prognostication, PET-CT adapted therapy in the neoadjuvant setting, and surveillance.
Reference57 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021
2. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023
3. Incidence of Esophageal Cancer in the United States from 2001–2015: A United States Cancer Statistics Analysis of 50 States;Patel;Cureus,2018
4. Epidemiology of Esophageal Squamous Cell Carcinoma;Abnet;Gastroenterology,2018
5. Esophageal carcinoma;Rustgi;N. Engl. J. Med.,2014